돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HCID 5284514생성일: 2026년 10월 23일

Acrivastine

https://huagongshe.com/ko/chemical/5284514

Acrivastine 분자 구조식

식별자 및 물리적 특성

CAS No.87848-99-5
분자식C22H24N2O2
평균 분자량348.4 g/mol
단동위원소 질량348.18377801 g/mol
SMILESCc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1
InChIKeyPWACSDKDOHSSQD-IUTFFREVSA-N
PubChem CID5284514
ChEMBLCHEMBL1224
ChEBICHEBI:83168
EC No.618-080-6
DTXSIDDTXSID6022555

화학 및 물리적 성질

XLogP1.6
극성 표면적53.4
수소 결합 공여자 수1
수소 결합 수용자 수4
회전 가능 결합 수6
무거운 원자 수26
형식 전하0
복잡도514
의약품Pharmaceuticals -> Listed in ZINC15
Human DrugsBreast FeedingLactationMilk, HumanAntihistaminesFDA approved drugs -> Active ingredient
Collision Cross Section193.9 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]

안전 및 규제

GHS 분류This chemical does not meet GHS hazard criteria for 50% (1 of 2) of reports.H413 (50%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]P273, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory.
Hazard Classes and CategoriesAquatic Chronic 4 (50%)
HepatotoxicityAcrivastine has not been linked to liver enzyme elevations or to instances of clinically apparent liver injury. Its relative safety may relate to its rapid metabolism and use in low dosages.
Drug Induced Liver InjuryDrug-Induced Liver Injury Severity and Toxicity (DILIst)AcrivastineDILI NegativeOralDOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation